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Abstract  
Background. The primary immunodeficiency diseases (PIDs) constitute a diverse and ever-
expanding group of inborn errors affecting a wide range of immune functions. They are not 
well documented in Sub-Saharan Africa. An important barrier to care is limited awareness of 
PIDs and their management among health care professionals. This fascinating spectrum of 
diseases is rapidly expanding worldwide, and not as rare as we think. Genetic characterization 
and newborn screening for primary Immunodeficiency diseases (PIDs) may be the gold 
standard in the first world setting but are neither practical nor feasible for our doctors. Yet, 
other low and middle income countries in the world have also established reasonable services 
and created registries for children with PIDs, including other African countries. 
Objective. To describe the spectrum of PIDs at a tertiary paediatric hospital. 
Methods. A retrospective descriptive study of PIDs diagnosed at Red Cross War Memorial 
Children’s Hospital, Cape Town, South Africa between 1975 and 2017 was undertaken.  
Results. 252 children with PIDs were identified, spanning 8 of the 9 categories listed in the 
2017 classification of the International Union of Immunological Societies. Predominantly 
antibody deficiencies, combined immunodeficiencies with associated syndromic features, and 
immunodeficiencies affecting cellular and humoral immunity accounted for 79% of all PIDs. 
The mean age (standard deviation) at diagnosis was 46 (50) months and the male to female 
ratio was 1.5:1. A history of parental consanguinity was present in 3 children (1.2%). Recurrent 
infection was the most prevalent presenting phenotype, manifesting in 70.2% of the patients. 
Genetic or chromosomal confirmation was obtained in 42/252 (16.7%) of the children. 
Common interventions used to prevent infection were antimicrobial prophylaxis and 
immunoglobulin replacement therapy, administered to 37.7% and 36.9% of the patients 
respectively. Six of seven children who underwent haematopoietic stem cell transplantation 
(HSCT) had successful outcomes. The 7th patient died 2 months post-HSCT from 
overwhelming infection. Although we could not account for the children lost to follow up 
during the study period, 53 (21.0%) deaths were confirmed. 
Conclusions. Several challenges exist in the recognition and treatment of children with PIDs 
in our setting. These include limited access to genetic diagnostics and HSCT. Sub-optimal 
treatment options contribute to the overall mortality of PIDs in South Africa. Greater awareness 
among clinicians treating children and more laboratory diagnostic capacity are needed to 
increase the recognition PIDs among children in South Africa. The treatment options that are 
available in South Africa are unevenly distributed. Hence, treatment capacity should be 
expanded throughout the country, especially advanced interventions such as HSCT. Ongoing 
reporting of registries such as ours and increased community awareness should strengthen the 
lobby for greater investment in rare diseases such as the PIDs.  
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1.1 Abstract  
Background. The primary immunodeficiency diseases (PIDs) constitute a diverse and ever-
expanding group of inborn errors affecting a wide range of immune functions. They are not 
well documented in Sub-Saharan Africa.  
Objective. To describe the spectrum of PIDs at a tertiary paediatric hospital. 
Methods. A retrospective descriptive study of PIDs diagnosed at Red Cross War Memorial 
Children’s Hospital, Cape Town, South Africa between 1975 and 2017 was undertaken.  
Results. 252 children with PIDs were identified, spanning eight of the nine categories listed in 
the 2017 classification of the International Union of Immunological Societies. Predominantly 
antibody deficiencies, combined immunodeficiencies with associated syndromic features, and 
immunodeficiencies affecting cellular and humoral immunity accounted for 199 (79%) 
children with PIDs. The mean age (standard deviation) at diagnosis was 46 (50) months and 
the male to female ratio was 1.5:1. A history of parental consanguinity was present in three 
children (1.2%). Recurrent infection was the most prevalent presenting phenotype, manifesting 
in 177 (70.2%) patients. Genetic or chromosomal confirmation was obtained in 42/252 (16.7%) 
of the children. Common interventions used to prevent infection were antimicrobial 
prophylaxis and immunoglobulin replacement therapy, administered to 95 (37.7%) and 93 
(36.9%) of the patients respectively. Six of seven children who underwent haematopoietic stem 
cell transplantation (HSCT) had successful outcomes. The seventh patient died two months 
post-HSCT from overwhelming infection. Although we could not account for the children lost 
to follow up during the study period, 53 (21.0%) deaths were confirmed. 
Conclusions. Several challenges exist in the recognition and treatment of children with PIDs 
in our setting. These include limited access to genetic diagnostics and HSCT. Sub-optimal 
treatment options contribute to the overall mortality of PIDs in South Africa. 
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1.2 Introduction 
Primary immunodeficiency diseases (PIDs) are inborn errors of immunity; a large 
heterogeneous group of predominantly genetic conditions that predispose individuals to a wide 
spectrum of infection, autoimmunity, autoinflammation, lymphoproliferation, malignancy, 
clinically recognisable syndromes in which immunodeficiency is a feature, allergic 
manifestations and end-organ damage causing chronic dysfunction. Without optimal treatment 
many PIDs are life-limiting.[1] Diagnosis is dependent on the type of infection and other 
presenting manifestations preceding diagnosis, immunological testing and, where possible 
confirmatory genetic testing.[2]  
The spectrum of PIDs is evolving rapidly with new PIDs being continuously described and 
molecularly characterised. Since 1970, the International Union of Immunological Societies 
(IUIS) has included 354 PIDs and 344 different gene defects in its consensus classification.[3] 
Worldwide, PIDs affect more than six million people and in Africa an estimated 988,000 adults 
and children have PIDs, of whom approximately 2,500 have been diagnosed.[4] In South Africa, 
the estimated total mid-2017 population was 56.52 million.[5] If it is assumed that the 
prevalence of PIDs in South Africa is similar to that in well-resourced countries, then the total 
number of adults and children with PIDs in our country should range between 3,040 and 
48,775. However, fewer than 500 PID cases have been reported from South Africa.[6,7] 
Children with PIDs have been managed at Red Cross War Memorial Children’s Hospital 
(RCWMCH) for more than 40 years.[8] An early review of the immunology laboratory database 
at the hospital during a 13-year period identified 93 children with PIDs, a mean of 6.6 new PID 
diagnoses per annum. Primary antibody deficiencies predominated, accounting for 56% of all 
PIDs, and the spectrum of PIDs was similar to that reported from Europe, and North and South 
America.[9] An analysis of 168 children with PIDs managed over a 27-year period at 
RCWMCH, showed that the mean age at the time of diagnosis declined significantly over the 
study period, suggesting that awareness of these diseases among clinicians had improved.[6] In 
contrast to the situation in North Africa where PIDs frequently occur in children with 
consanguineous parents, consanguinity was highly unusual in the RCWMCH cohort, occurring 
in less than 2% of the patients.[6,10-12] High background consanguinity rates in North Africa and 
the Middle East alters the spectrum of PIDs compared to other geographical regions, with 
autosomal recessive conditions being more frequent than X-linked or autosomal dominant 
diseases.[13]  
The current IUIS classification of PIDs includes a broad spectrum of conditions.[3] 
Consequently, at RCWMCH several sub-specialist services participate in the management of 
children with PIDs including rheumatology, haematology & oncology, cardiology, allergology, 
pulmonology gastroenterology and neurology. Previous descriptive studies from RCWMCH 
have been confined to PID patients managed by the immunology and infectious diseases 
services.[9,6] The present study aims to provide a more comprehensive understanding of the 
spectrum of PIDs across all sub-specialist services at our hospital and further raise awareness 
of PIDs among South African clinicians.  
 
 
 
 11 
 
1.3 Methods 
Study design and setting  
This retrospective, descriptive study was completed at RCWMCH, a 273-bed, tertiary-referral 
facility situated in the Western Cape Province and affiliated to the University of Cape Town. 
It accepts paediatric referrals from diverse sources, in both primary and tertiary settings. 
Intentionally a unique situation, providing sub-specialist consultation to doctors throughout 
South Africa, but predominantly from facilities managing children in the Western Cape 
Province. A dedicated service for the diagnosis and treatment of PIDs was established at 
RCWMCH in the mid-1970s.[14] In 2008 the PID service became part of the infectious diseases 
service at the hospital. Since 1983 information on all children with PIDs (1) who were 
diagnosed and/or treated, or (2) for whom diagnostic / treatment advice was provided to their 
attending clinicians by the PID or infectious diseases services was maintained in a dedicated 
database, henceforth referred to as the PID database. Because of the multi-system nature of 
many PIDs, some children are increasingly being managed by sub-specialist services other than 
the infectious diseases service at RCWMCH and hence not included in the PID database. To 
address this gap in the PID database and describe the full spectrum of PIDs managed or 
supported by all sub-specialist services at RCWMCH between 1 January 1975 and 31 
December 2017, the infectious diseases service collaborated with several specialist / sub-
specialist services managing children with PIDs.  
Classification of primary immunodeficiency diseases 
Patients were classified according to the  International Union of Immunological Societies 
(IUIS) 2017 report on inborn errors of immunity and the IUIS 2017 phenotypic 
classification[3,15] and adapted where necessary using Stiehm’s textbook on immune 
deficiencies.[16] Because mutational analysis is not routinely available in South Africa most 
PID diagnoses are based on the clinical and immunologic phenotype, hence the nomenclature 
used to describe specific PIDs was appropriately adapted.[6] Furthermore, diagnostic criteria 
formulated by the Pan-American Group for Immunodeficiency (PAGID) and the European 
Society for Immunodeficiency (ESID) were used to diagnose some conditions such as IgA 
deficiency and common variable immunodeficiency (CVID).[17] 
Data collection 
Relevant clinical and laboratory data were extracted from hospital folders and the National 
Health Laboratory Service (NHLS) database using a standardised case record form that is used 
by the infectious diseases service in the management of patients with PIDs. Information 
included patient demographics, presenting problems, results of immunological investigation, 
treatment modalities, complications, and the outcome, if known. The data were transferred 
anonymously in a study-specific Excel spreadsheet. 
Data analysis 
Data were analysed using Stata software (StataCorp. 2013. Stat Statistical Software: Release 
13. College Station, TX: StataCorp LP). Proportions were expressed as percentages. 
Continuous variables were tested for normality using the Shapiro-Wilks test. Mean and 
standard deviation or median and interquartile range (IQR) were used to describe the data as 
appropriate.  
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Ethics considerations 
The research protocol was approved by the Human Research Ethics Committee, Faculty of 
Health Sciences, University of Cape Town (HREC Ref 191/2017) and the RCWMCH research 
committee. Patient consent was not obtained because the analysis was done retrospectively. 
The study was completed in accordance with the Declaration of Helsinki. 
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1.4 Results  
Patient population 
All children entered into the existing PID database during the study period were reviewed to 
confirm the accuracy of their diagnoses. Of 230 children in the database reviewed, 12 were 
excluded because there was no conclusive evidence that they had PIDs. The remaining 218 
with PIDs were retained in the study database. Ten other specialist / sub-specialist services 
referred 206 children with possible PIDs. These 206 patients were derived from outpatient 
attendance lists, clinical databases, the National Health Laboratory Services (NHLS) 
cytogenetics database and senior clinician memory. Clinical and laboratory records of these 
patients were reviewed and a further 34 appropriately investigated children with PIDs were 
identified and added to the study database. Thus, 252 children with PIDs were identified and 
included in the current analysis (Figure 1).  
Spectrum of PIDs 
The number of new PID diagnoses in any five year period fluctuated throughout the study 
period with no clear trend. The 2010 to 2014 period realised the highest number of new PID 
diagnoses (Figure 2). 
The spectrum of PIDs among the 252 children (Table 1) spanned eight of the nine categories 
listed in the 2017 IUIS report on inborn errors of immunity. Among the 252 patients, 
predominantly antibody deficiencies, combined immunodeficiencies with associated 
syndromic features, and immunodeficiencies affecting cellular and humoral immunity (Table 
1) were most prevalent. This accounted for 79% of PIDs included in this study.  
Patient characteristics  
The mean age (standard deviation) at the time of diagnosis was 46 (50) months. The male to 
female ratio was 1.5:1. There were greater numbers of males in five of the eight PID categories 
(Table 1). Thirty-six patients (14.3%) were known to have a family history of PIDs. A history 
of parental consanguinity was present in three (1.2%) of the children, one each with chronic 
granulomatous disease, severe combined immunodeficiency caused by a mutation in 
recombination activating gene-1 (RAG1) deficiency and glycogen storage type 1b. The 
majority of patients, 181 (71.8%), lived in the Western Cape and a substantial number of 
patients were in the public sector of health (Table 2). 
 
Clinical presentation  
Recurrent infection was the commonest presenting phenotype manifesting in 177 (70.2%) of 
patients. Atypical infection and failure to thrive manifested in 38 (15.8%) and 51 (20.2%) 
patients, respectively. Invasive meningococcal infection was the presenting feature in nine 
children with complement component deficiencies, of whom six manifested with recurrent 
meningococcal infection and three with a single episode of infection before diagnosis. One 
child was diagnosed after screening based on a family history of complement C5 deficiency. 
Dysmorphic features or recognisable clinical syndromes occurred in 52 (20.6%) patients. The 
three commonest syndromes were DiGeorge, now formally called 22q11.2 deletion syndrome, 
Ataxia-telangiectasia and Hyper IgE syndrome, occurring in 23 (9.1%), 15 (6.2%) and 9 (3.6%) 
of the patients, respectively (Table 1). Six of the seven children with C1 inhibitor deficiency 
presented with angioedema, while the remaining patient, an older brother of one of the other 
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patients was screened based on the family history and diagnosed before he manifested 
clinically. The five children with autoinflammatory disorders presented with non-infectious 
manifestations, commonly persistent fever. 
Genetic or chromosomal confirmation 
Molecular characterisation is not routinely available in South Africa but was undertaken in a 
subset of the patient cohort.  Single gene mutations were confirmed in 24 (9.5%) patients of 
the cohort and chromosomal deletions in a further 18 (7.1%) children (Table 3). 
Management 
The predominant interventions administered to prevent infection were antimicrobial 
prophylaxis, 95/252 (37.7%) and immunoglobulin replacement therapy, 93/252 (36.9%). 
Antimicrobial prophylaxis plus immunoglobulin replacement therapy was administered to 
31/252 (12.3%) patients. Seven children underwent haematopoietic stem cell transplantation 
(HSCT). The first HCST for a child with SCID caused by IL-2 receptor γ-chain deficiency took 
place in 1996 (Brian Eley, personal communication). Six of the seven patients had SCID and 
one IPEX syndrome. Six of these patients experienced complete immunological reconstitution 
and are well. The seventh patient who underwent HSCT for underlying SCID died two months 
after HSCT from presumed septicaemia complicated by multi-organ failure. Other treatment 
interventions included subcutaneous interferon-γ administration in two patients with chronic 
granulomatous disease. The treatment of patients with C1 inhibitor deficiency included fresh 
frozen plasma during acute attacks and tranexamic acid prophylaxis. In the patients with 
autoinflammatory disorders, treatment included colchicine (3 patients), methotrexate (2 
patients) and adalimumab, an anti-tumour necrosis factor-α inhibitor (1 patient). 
Mortality 
During the study period, 53 (21.0%) patients died. The cause of death was not known in 12 
patients. In the remaining 40 patients, the most frequent causes of death were presumed or 
proven septicaemia, 15 patients (37.5%) and pneumonia, nine patients (22.5%). Of 47 patients 
with a known date of death, death occurred within one year of PID diagnosis in 32 (68.1%), 
including 15 (31.9%) who died within one month of PID. Of the remainder, seven (14.9%) 
died between one and five years after PID diagnosis and eight (17.0%) died more than five 
years after PID diagnosis (Table 4).  
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1.5 Discussion  
Worldwide, PIDs are an ever-expanding disease group as a result of the description of new 
genetic disorders. The burden of secondary immunodeficiencies such as HIV infection and 
severe acute malnutrition continues to overshadow that of the PIDs in low-and-middle-income 
countries (LMICs) including South Africa, resulting in limited investment in the diagnostic and 
treatment resources needed for PIDs. Despite the advancing knowledge base and expertise of 
PIDs national incidence and prevalence estimates are largely unknown. An important barrier 
to care is limited awareness of PIDs and their management among health care professionals, as 
well as in the broader society. A study completed in the United States and published in 2016 
showed that few family practice physicians were aware of guidelines for diagnosing and 
managing PIDs compared to subspecialist immunologists, 4% versus 79%.[18] In the present 
study we document the spectrum of PIDs among 252 children diagnosed at a tertiary hospital 
in South Africa over a period of more than 40 years. Although diagnosis depended mainly on 
clinical and immunological criteria, we were able to classify our patients using the latest IUIS 
classification. The spectrum of PIDs in this study spanned eight of the nine categories in the 
IUIS classification. The ninth category, phenocopies of inborn errors of immunity was only 
added to the IUIS classification very recently, in 2015, and many of the diseases in this category 
manifest in adulthood, hence the absence of these PIDs among our patients.[3]  
Parental consanguinity was identified in only 1.2 % of our patients.[13] By contrast in the North 
African countries of Morocco, Tunisia and Egypt, parental consanguinity rates of 43.2%, 
58.2% and 62.5% respectively were documented.[10-12] These high parental consanguinity rates 
result in higher proportions of PIDs due to Mendelian autosomal recessive inheritance, lower 
proportions of PIDs due to Mendelian X-linked inheritance, and consequently a predominance 
of combined cellular and humoral immunodeficiency in comparison to the preponderance of 
predominantly antibody deficiencies in populations with low consanguinity rates.[13] An 
analysis of the ESID registry in June 2014 showed that 56.78% of 19,355 children and adults 
with PIDs had predominantly antibody deficiencies.[19] In our study predominantly antibody 
deficiencies account for 40.5% of all PIDs, whereas in the registries of Morocco and Tunisia 
predominantly antibody immunodeficiencies account for 22.8% and 17.7% of all PIDs 
respectively.[11,12]  
The mean age of our patients was 46 months similar to the mean age of children in the Egyptian 
study of 51 months.[10] The mean ages at diagnosis in the Moroccan and Tunisian registries 
were 6.2 years and 5.3 years respectively.[11,12] However, both these registries included children 
and adults with PIDs. A previous analysis from our hospital published in 2011 documented a 
mean age at diagnosis of 51 months and a statistically significant decline in mean age over 
time, suggesting that awareness of the PIDs had increased among clinicians at our hospital 
during the study period. [6] Although most of our patients emanated from the public sector, 
36.9% originated from the private sector. Given that approximately 20% of the South African 
population are serviced in the private sector, this result suggests that more effort may be needed 
to increase awareness of the PIDs among public sector clinicians.  
Genetic or chromosomal confirmation of PID diagnosis was obtained in 16.7% of our patients, 
somewhat higher than 13.8% genetic confirmation reported in 2015 among PID patients in the 
Tunisian registry. [11] In Europe where molecular testing is more accessible, the rate of genetic 
diagnostic confirmation is much higher having reached 36% of all patients registered with 
ESID registry in April 2018. [20]  
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Most interventions for managing PIDs are available to a varying degree in South Africa, 
including optimal immunisation practice, antimicrobial therapy and prophylaxis, 
immunoglobulin replacement therapy and infection control measures.[2] Some interventions 
such as interferon-1-inhibitors and HSCT are extremely expensive, limiting accessibility 
within the public sector. HSCT is the treatment of choice for many severe PIDs. Our findings 
demonstrate that it is possible to successfully undertake HSCT in patients with PIDs in South 
Africa. However, only a small proportion of more than 50 patients who may have benefitted 
were transplanted. Reasons for the low number of transplants include late presentation of 
patients often with severe complications of their underlying PIDs, the small donor pool in South 
Africa resulting in the unavailability of suitable matched unrelated donors, high cost of 
accessing donors affiliated to international registries, and no paediatric ICU facilities at the 
adult tertiary referral hospital where our paediatric transplants were undertaken. In 2012 the 
first HLA haplo-identical HSCT was performed for SCID. Before, 2012, only HLA identical 
or matched unrelated donors were considered for children with SCID. Transplantation 
programmes have also been started in North African countries such as Tunisia and Morocco. 
[11, 12] 
Unfortunately, we had limited access to patient outcomes, especially those lost to follow up.    
We are however able to describe the  mortality of 21%, which compares with mortality 
documented in studies with similar challenges completed in Egypt, Morocco and Tunisia of 
23.4%, 28.8% and 34.5% respectively.[10-12] In our study, 36% of known deaths occurred in 
patients with SCID, and 68% of deaths including 19 preceded by SCID occurred during the 1st 
year after PID diagnosis indicating the  need to focus on optimising the outcome of children 
with SCID because there is a high chance of achieving immunological cure after successful 
HSCT. In the Tunisian study, 17.2% of patients were lost to follow up indicating that maybe 
this is an important consideration for patients with PIDs residing in other LMICs. [11] 
Strengths and limitations 
This study is the largest single centre description of PIDs in children in Sub-Saharan Africa to 
date. We were able to include more than 250 patients because we adopted an expanded search 
strategy among sub-specialist services at our hospital. Furthermore, despite limited genetic 
confirmation, we were able to classify our patients using the latest IUIS classification system. 
Because of the retrospective study design, there were limitations in the availability and 
completeness of the clinical data. Outcome data was limited to known deaths. Because some 
of the patients were treated by their referring doctors with minimal or no feedback, the true 
mortality prevalence was not established and hence we did not explore risk factors associated 
with death. We could not comprehensively document those lost to follow up and hence have 
an incomplete understanding of the true extent of this outcome measure amongst our patients. 
Review of patients referred by other sub-specialist services showed that a sizeable proportion 
was not adequately investigated for immunodeficiency. For example, of 73 patients with 
laboratory confirmed 22q11 deletion, 37 (50.7%) had not been investigated for 
immunodeficiency, and hence these could not be considered for inclusion in our study 
population. Likewise of 15 patients with right-sided isomerism 11 had not been investigated 
for asplenia. Furthermore, it is likely that more cases of PID were missed during the study 
period because either PIDs was not considered or the children presented with milder PID 
phenotypes. Although this reality prevented us from achieving complete description of PIDs at 
our hospital during the study period, our results did allow us to largely address the stated aim 
and provide direction for improving our clinical service. 
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1.6 Conclusion 
In the present study we were able to collate the findings of 252 patients with a spectrum of 50 
primary immunodeficiency diseases over a period of more than 4 decades. Greater awareness 
among clinicians treating children and more laboratory diagnostic capacity are needed to 
increase the recognition PIDs among children in South Africa. The treatment options that are 
available in South Africa are unevenly distributed. Hence, treatment capacity should be 
expanded throughout the country, especially advanced interventions such as HSCT. Ongoing 
reporting of registries such as ours and increased community awareness should strengthen the 
lobby for greater investment in rare diseases such as the PIDs.  
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1.8 Figures  
Figure 1 
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Figure 2 
 
 
 
 
Figure 2: Number of new primary immunodeficiency diagnoses, 1975 - 2017 
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1.9 Tables  
 
Table 1: Spectrum of primary immunodeficiency diseases, 1975 – 2017 
 
 
PID category 
 
 Gender 
Total (%) Males Females 
Immunodeficiencies affecting cellular and humoral immunity 
45 (17.9) 30 15 
T-B+ Severe combined immunodeficiency (SCID) 16 ( 6.3) 15 1 
T-B-SCID 9 (3.6) 2 7 
CD40 ligand deficiency 4 (1.6) 4 0 
Hyper IgM syndrome (autosomal) 2 (0.8)  2 
Hyper IgM syndrome (unspecified) 3 (1.2) 2 1 
Combined CD4 and CD8 deficiency 8 (3.2) 5 3 
Idiopathic CD4 lymphopaenia 3 (1.2) 1 2 
CD8 deficiency 1 (0.4) 1 0 
Combined immunodeficiencies with associated or syndromic features 
52 (20.6) 26 26 
Wiskott-Aldrich syndrome 4 (1.6) 3 1 
Ataxia-telangiectasia 15 (6) 6 9 
Chromosome 22q11.2 deletion syndrome 18 (7.1) 10 8 
DiGeorge syndrome, genetic defect unknown 5 (2) 2 3 
Hyper IgE Syndrome, mutation undefined 7 (2.8) 4 3 
Hyper IgE,with STAT3 mutation 1 (0.4) 1 0 
Hyper IgE, without a mutation  in STAT3, DOC8 or TYK2 1 (0.4) 0 1 
Comel-Netheton syndrome  1 (0.4) 0 1 
Predominantly antibody deficiencies 102 (40.5) 66 36 
B- panhypogammaglobulinaemia    
           XL agammaglobulinaemia 18 (7.1) 18 0 
           AR hypogammaglobulinaemia 2 (0.8) 0 2 
B+ Hypogammaglobulinaemia    
          Common variable immunodeficiency 28 (11.1) 18 10 
          Transient hypogammaglobulinaemia of infancy 25 (9.9) 18 7 
          Hypogammaglobulinaemia undefined 3 (1.2) 1 2 
Selective IgA Deficiency 12 (4.8)) 7 5 
IgG subclass deficiency with IgA deficiency 6 (2.4) 1 5 
Isolated IgG subclass deficiency 6 (0.02) 3 3 
Specific antibody deficiency with normal Ig levels and normal B cells 2 (0.8) 0 2 
Diseases of immune dysregulation 2 (0.8) 1 1 
Chediak-Higashi Syndrome 1 (0.4) 0 1 
Immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome 1 (0.4) 1 0 
Congenital defects of phagocyte number or function 22 (8.7) 15 7 
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Congenital neutropenias    
        Congenital neutropaenia, AD inheritance 2 (0.8) 1 1 
        Glycogen Storage disease Type 1b 3 (1.2) 1 2 
       Cyclic neutropenia 1 (0.4) 1 0 
       Shwachman- Diamond Syndrome 1 (0.4) 0 1 
       Congenital neutropaenia, inheritance undefined 5 (2) 3 2 
Chronic granulomatous disease, confirmed XL inheritance 1 (0.4) 1 0 
Chronic granulomatous disease, AR inheritance 1( 0.4) 0 1 
Chronic granulomatous disease, mutation undefined  7 (2.7) 7 0 
Myeloperoxidase deficiency 1 (0.4) 1 0 
Defects in intrinsic and innate immunity 6 (2.4) 4 2 
Warts, hypogammaglobulinaemia, infections & myelokathexis (WHIM) syndrome 1 (0.4) 1 0 
Chronic mucocutaneous candidiasis 1 (0.4) 0 1 
Congenital asplenia with right-sided isomerism 4 (1.6) 3 1 
Autoinflammatory disorders 6 (2.4) 4 2 
Defects effecting the inflammasome    
       Familial Mediterranean Fever 2 (0.8) 2 0 
      Mevalonate kinase deficiency (Hyper-IgD Syndrome) 1 (0.4) 0 1 
Non-inflammasome-related conditions    
       Pyrogenic sterile arthritis,  pyoderma gangrenosum, acne (PAPA) syndrome  1 (0.4) 1 0 
       Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) 
syndrome 1 (0.4) 1 0 
      Chronic recurrent multifocal osteomyelitis (CRMO) syndrome  1 (0.4) 0 1 
Complement deficiencies 17 (6.7) 7 10 
C5 Deficiency 2 (0.8) 0 2 
C6 deficiency 7 (2.7) 4 3 
Complement deficiency, undefined 1 (0.4) 0 1 
    C1 inhibitor deficiency 7 (2.7) 3 4 
All PID categories 252 (100) 153 (60.7) 99 (39.3) 
PID= primary immunodeficiency disease; XL = X-linked; AR = autosomal recessive 
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Table 2: Patient Characteristics at the time of PID diagnosis 
 
 
 
Patient Characteristics N = 252 
Age (months) (SD) 46 (50) 
 
Age Category (months), n (%)  
     < 12 
     12 - 60 
   > 60 
   
 
76 (30.1) 
98 (38.9) 
78 (31.0) 
 
Gender, n (%) 
    Male 
    Female 
 
Male to Female ratio 
 
 
153 (60.7) 
99 (39.3) 
 
1.5 : 1 
 
Family History of PIDs, n (%) 
 
36 (14.3) 
Parental consanguinity, n (%) 3 (1.2) 
Provincial residence, n (%) 
   Western Cape  
   Eastern Cape 
   Gauteng  
   Free State 
   Kwa Zulu Natal  
   Northern Cape  
   Unknown 
 
181 (71.8) 
25 (9.9) 
17 (6.7) 
7 (2.8) 
6 (2.3) 
8 (3.2) 
8 (3.2) 
 
Health Sector classification, n (%) 
   Private 
   Public 
   Unknown 
 
93 (36.9) 
151 (59.9) 
8 (3.2) 
PID = primary immunodeficiency disease; SD = standard deviation 
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Table 3: Spectrum of PIDs with confirmed genetic or chromosomal abnormalities 
 
 
 
Primary 
immunodeficiency 
disease 
Genetic / 
chromosomal 
defect 
Inheritance OMIM Number  
X linked 
agammaglobulinaemia 
BTK XL 300300 5 related 
patients 
CD40 ligand Deficiency CD40LG XL 300386 3 male 
siblings 
T-B+NK- SCID IL2RG  AR 308380 4 unrelated 
patients 
T-B-NK+ SCID RAG1 AR 179615 1 patient 
Hyper IgE Syndrome STAT3 AD 102582 1 patient 
X inked chronic 
granulomatous disease 
CYBB XL 300481 1 patient 
Hyper-IgD syndrome MVK AR 260920 1 patient 
C6 Deficiency C6 AR 217050 3 unrelated 
patients 
C5 Deficiency  C5 AR 120900 2 unrelated 
patients 
Immune dysregulation, 
polyendocrinopathy, 
enteropathy, X linked 
(IPEX) syndrome 
FOXP3  XL 300292 1 patient 
DiGeorge Syndrome  22q11.2 
deletion 
  18 unrelated 
patients 
XL = X-linked; AR = autosomal recessive; AD = autosomal dominant; OMIM = Online Mendelian Inheritance 
in Man 
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Table 4: PIDs in children who died 
 
Primary immunodeficiency disease Number (%) 
 N = 53 
Severe combined immunodeficiency (SCID) 19 (35.8) 
X-linked agammaglobulinaemia 9 (17.0) 
B+ hypogammaglobulinaemia 4 (7.5) 
Ataxia-telangiectasia 4 (7.5) 
DiGeorge syndrome 4 (7.5) 
CD40 ligand deficiency 3 (5.7) 
Chronic granulomatous disease 3 (5.7) 
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2. Appendicies 
 
2.1 Immunology data collection sheet 
 
 
Biographical data (If available, use sticker to complete some of the data fields) 
 
Study number:     Folder number:    
 
Date of birth(Y-M-D):   Date of testing:    
 
Age (months):      
 
Suburb (Cape Town)          
            
 
Referral source 
 
 State    Private   Outpatient    Inpatient, specify ward:   
 
 Cape Town    Western Cape    Another province, specify:    
 
Referring doctor:______________________Contact number:__________________  
 
Indication(s) for investigation 
 Recurrent infection    Failure to thrive    Family history    Reaction to live-attenuated vaccines, 
specify:         
 Dysmorphic features, specify:        
 28 
 
 Other, specify:          
History of chief complaint (e.g. list major infections & dates, spectrum of infections, frequency of 
infections, associated hospitalisation): 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
______________________ 
__________________________________________________________________________________
____________________________________________________ 
 
Family History 
 Consanguity (Y / N)     Primary immunodeficiency, specify:   
 ______________________________________________________________ Early 
childhood deaths, specify:         
           
Family tree  
 
 
 
 
 
 
 
 
Investigations 
Previous investigations 
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 Date Results 
HIV rapid   
HIV DNA PCR   
White cell count (x 109/L)   
Neutrophil count (x 109/L)   
Lymphocyte count (x 109/L)   
Total protein, Albumin   
Mantoux   
Sweat test   
Allergy testing   
Other tests   
   
   
 
Immunoglobulins (g/L) 
 
 Results Reference range 
IgG   
IgA   
IgM   
IgE   
IgG1   
IgG2   
IgG3   
IgG4   
Measles antibody titre   
Tetanus antibody titre   
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Pneumococcal antibody titre   
Other (specify)   
 
 
 
 
 
Lymphocyte subsets (x 109/L) 
 
 Percentage 
count 
Absolute count Reference range 
(absolute count) 
CD3+    
CD3+ CD4+ (Helper cells)    
CD3+CD8+ (Suppressor cells)    
CD19/20+ (B-cells)    
CD16/56+ (NK cells)    
DR+ (activated lymphocytes)    
 
Lymphocyte stimulation tests 
 
Patient results 
Phycohaemaglutinin (PHA)  
   Stimulation index  
Concanavalin A (Con A)  
   Stimulation index  
Protein A (Prot A)  
   Stimulation index  
Pokeweed (PWM)  
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   Stimulation index  
Control results 
Phycohaemaglutinin (PHA)  
   Stimulation index  
Concanavalin A (Con A)  
   Stimulation index  
Protein A (Prot A)  
   Stimulation index  
Pokeweed (PWM)  
   Stimulation index  
 
Complement tests 
 
 Results Reference range 
Total haemolytic complement   
Component assay (specify): 
 
  
 
 
  
 
Oxidative burst test 
 
Patient results 
Oxidising neutrophils: resting  
Oxidising neutrophils: stimulated  
Control results 
Oxidising neutrophils: resting  
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Oxidising neutrophils: stimulated  
 
Other tests (specify):           
 
Sample bank 
 
 serum           DNA            PBMCs               EBV-transformed cells    
Other (specify): 
 
Comment (results) 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________ 
 
Diagnosis 
__________________________________________________________________________________
____________________________________________________ 
 
Associated problems (at diagnosis) 
__________________________________________________________________________________
____________________________________________________ 
___________________________________________________________________ 
 
Treatment 
 Antibiotic prophylaxis    IVIG       BMT 
 Other (specify):         
Treatment details (e.g. duration IVIG, BMT type/induction): 
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__________________________________________________________________________________
____________________________________________________ 
___________________________________________________________________ 
 
Complications & outcome (e.g. complications after diagnosis, hospitalisation, cancers, death, lost-to-
follow-up; include dates) 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
___________________________________________________________________ 
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2.2 Ethics  approval  letter                                                      
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2.3 Hospital  approval  letter 
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2.4 Latest progress report approved by Ethics Committee 
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2.5 Protocol  amendments approved by Ethics committee 
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publication fee should the article be accepted for publication. The publicaiton fee is payable 
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publication. The submitting author will be notified that payment is due and given details on 
the available methods of payment. Prompt payment is advised; the article will not enter into 
production until payment is received. 
Queries can be directed to claudian@hmpg.co.za. 
 
Please refer to the section on ‘Sponsored Supplements’ regarding the publication of 
supplements, where a charge is applicable. Queries can be directed to dianes@hmpg.co.za 
or claudian@hmpg.co.za 
Authorship 
 43 
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critical revision of important scientific content; or (iii) approval of the version to be published. 
These conditions must all be met (uniform requirements for manuscripts submitted to 
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If authors’ names are added or deleted after submission of an article, or the order of the 
names is changed, all authors must agree to this in writing. 
  
Please note that co-authors will be requested to verify their contribution upon submission. 
Non-verification may lead to delays in the processing of submissions. 
Author contributions should be listed/described in the manuscript. 
  
Conflicts of interest 
Conflicts of interest can derive from any kind of relationship or association that may influence 
authors’ or reviewers’ opinions about the subject matter of a paper. The existence of a conflict 
– whether actual, perceived or potential – does not preclude publication of an article. However, 
we aim to ensure that, in such cases, readers have all the information they need to enable 
them to make an informed assessment about a publication’s message and conclusions. We 
require that both authors and reviewers declare all sources of support for their research, any 
personal or financial relationships (including honoraria, speaking fees, gifts received, etc) with 
relevant individuals or organisations connected to the topic of the paper, and any association 
with a product or subject that may constitute a real, perceived or potential conflict of interest. 
If you are unsure whether a specific relationship constitutes a conflict, please contact the 
editorial team for advice. If a conflict remains undisclosed and is later brought to the attention 
of the editorial team, it will be considered a serious issue prompting an investigation with the 
possibility of retraction. 
  
Research ethics committee approval 
Authors must provide evidence of Research Ethics Committee approval of the research where 
relevant. Ensure the correct, full ethics committee name and reference number is included in 
the manuscript. 
If the study was carried out using data from provincial healthcare facilities, or required active 
data collection through facility visits or staff interviews, approval should be sought from the 
relevant provincial authorities. For South African authors, please refer to the guidelines for 
submission to the National Health Research Database. Research involving human subjects must be 
conducted according to the principles outlined in the Declaration of Helsinki. Please refer to 
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structuresto ensure that the appropriate requirements for conducting research have been met, 
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Clinical trials 
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should be 
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register, if relevant), and the trial registration number should be cited at the end of the 
abstract. All clinical trial reports must also contain a data sharing statement as per the 
recommendations of the ICMJE. Statements are to indicate: 
• whether individual deidentified participant data will be shared; 
• what data in particular will be shared; whether additional, related documents will be available; 
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system will not be made available to third parties without the user’s permission or due 
process. By registering to use the website or submission system, users consent to receive 
communication from the SAMJ or its publisher HMPG on matters relating to the journal or 
associated publications. Queries with regard to privacy may be directed to 
publishing@hmpg.co.za. 
  
Ethnic/race classification 
Use of racial or ethnicity classifications in research is fraught with problems. If you choose to 
use a research design that involves classification of participants based on race or ethnicity, or 
discuss issues with reference to such classifications, please ensure that you include a detailed 
rationale for doing so, ensure that the categories you describe are carefully defined, and that 
socioeconomic, cultural and lifestyle variables that may underlie perceived racial disparities 
are appropriately controlled for. Please also clearly specify whether race or ethnicity is 
classified as reported by the patient (self-identifying) or as perceived by the investigators. 
Please note that is not appropriate to use self-reported or investigator-assigned racial or 
ethnic categories for genetic studies. 
  
Continuing Professional Development (CPD) 
SAMJ is an HPCSA-accredited service provider of CPD materials. Principal authors can earn up 
to 15 CPD continuing education units (CEUs) for publishing an article; co-authors are eligible 
to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. Each month, SAMJ also 
publishes a CPD-accredited questionnaire relating to the academic content of the journal. 
Successful completion of the questionnaire with a pass rate of 70% will earn the reader 3 
CEUs. Administration of our CPD programme is managed by Medical Practice Consulting. To 
complete questionnaires and obtain certificates, please visit MRP Consulting 
  
Manuscript preparation 
Preparing an article for anonymous review 
  
To ensure a fair and unbiased review process, all submissions are to include an anonymised 
version of the manuscript. The exceptions to this are Correspondence, Book reviews and 
Obituary submissions. 
  
Submitting a manuscript that needs additional blinding can slow down your review process, 
so please be sure to follow these simple guidelines as much as possible: 
• An anonymous version should not contain any author, affiliation or particular institutional 
details that will enable identification. 
• Please remove title page, acknowledgements, contact details, funding grants to a named 
person, and any running headers of author names. 
• Mask self-citations by referring to your own work in third person. 
  
  
General article format/layout 
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Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-point 
Times New Roman font, and contain no unnecessary formatting (such as text in boxes). 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) and contact 
details of ALL authors must be provided in the manuscript and in the online submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
• Include sections on Acknowledgements, Conflict of Interest, Author Contributions and Funding 
sources. If none is applicable, please state ‘none’.  
• Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but '50%' 
and '19ºC'. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B for 
beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the text. You may use the table 
format –this is the only exception. Please DO NOT use fill, format lines and so on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, although 
they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ can 
be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
• Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
• HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
• OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
• Bennet et al. Standardized human pedigree nomenclature: Update and assessment of the 
recommendations of the National Society of Genetic Counselors. J Genet Counsel 2008;17:424-
433: standard human pedigree nomenclature. 
Preparation notes by article type 
• Research 
• Editorials 
• CME 
• In Practice and Case reports 
• Reviews 
• Clinical trials 
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• Correspondence 
• Obituaries 
• Book reviews 
• Guidelines 
  
Research 
Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that clearly 
lay out the rationale for conducting the study. Some common reasons for conducting a study 
are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need 
to. Results should describe the study sample as well as the findings from the study itself, but 
all interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The 
conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
  
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the intervention, 
primary and secondary outcomes, any specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample description; outline the results 
according to the methods described. Primary outcomes must be described first, even if they 
are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
• Do not include any references in the abstracts. 
  
  
Here is an example of a good abstract. 
  
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
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• Objectives (within Introduction/Background): a clear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational attainment, co-existing disease 
indicators, etc)that may have an impact on the study results. Clearly define how participants 
were enrolled, and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically for randomised 
controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key characteristics of comparison 
groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, 
the exact level of statistical significance and the number need to treat/harm. Whenever 
possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is to present 
this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean 
(SD). 
• Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 
not go beyond the data in the article. 
  
Editorials 
Guideline word limit: 1 000 words 
  
These opinion or comment articles are usually commissioned but we are happy to consider 
and peer review unsolicited editorials. Editorials should be accessible and interesting to 
readers without specialist knowledge of the subject under discussion and should have an 
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element of topicality (why is a comment on this issue relevant now?) There should be a clear 
message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
• expert opinion 
• personal clinical experience 
• observational studies 
• trials 
• systematic reviews. 
  
CME (by invite only) 
CME is intended to provide readers with practical, up-to-date information on medical and 
related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to adhere 
strictly to the guidelines on word count as we have a page limit for the print issue of the SAMJ. 
We reserve the right to place some tables and reference lists online if this is necessary for 
space. 
In practice, this means that each CME topic usually covers two issues of the print issue of 
the SAMJ. 
  
The guest editor, in consultation with the editor, is responsible for convening a team of 
authors, deciding on the subjects to be covered and for reviewing the manuscripts submitted. 
The suggestion is for 4 - 5 articles, although there is some room for flexibility contingent on 
discussions with the editor. 
  
For queries about these guidelines please feel free to contact the CME editor, Dr Bridget 
Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)21 789 2331). 
  
Review process 
The guest editor reviews the articles and returns them to the CME editor for review and final 
approval. 
  
Guest editorials 
Guideline word limit: 1 000 words 
• Include the guest editor’s personal details (qualifications, positions, affiliation, e-mail address, 
and a short personal profile (50words)). 
• If possible, include a photograph of the author(s) at high enough resolution for print. It is 
preferable to provide two guest editorials, one for each issue, so that the content of the articles 
in each issue is covered. 
  
Articles 
Guideline word limit: 2 000 - 3 000 words 
• Each article requires an abstract of ±200 words. 
• The editor reserves the right to shorten articles but will send a substantially shortened article 
back for author approval. 
  
Personal details 
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Please supply: Your qualifications, position and affiliations and MP number (used for CPD 
points); Address, telephone number and fax number, and your e-mail address; and a short 
personal profile (50words)and a few words about your current fields of interest. 
  
In Practice 
Guideline word limit: 2 000 - 3 000words 
  
This section includes articles that would previously have been accepted into the Forum section, 
and case reports. 
In practice articles are those that draw attention to specific issues of clinical, economic or 
political interest regarding medicine and healthcare in southern Africa. They are assigned to 
a topic: 
  
• Case report 
• Clinical practice 
• Clinical alert 
• Issues in medicine 
• Issues in public health 
• Healthcare delivery 
• Consensus/Position statement 
• Medicine and the environment 
• Medicine and the law 
• Cochrane corner 
  
  
An In Practice article should follow the following format – sub-headings are not necessary, 
but may be used for clarity: 
• Author affiliations and qualifications: to be the same as for Research. Provide all authors’ names 
and initials, qualifications and full affiliations, and corresponding author. 
• Short abstract: does not need to be structured, but should capture the essential features of 
the article 
• Introduction: the reason for the article and the issue being addressed 
• Recent research, discussion, local policy around the issue – include your own research where 
appropriate 
• All statements should be referenced and, if opinion only, this should be stated 
• Discussion: how this article adds to the discussion around a particular topic 
• If a clinical practice or policy point is at issue, this needs to be emphasised, using a box with 
highlights if appropriate. 
  
Essentially In practice is an opportunity for a more discursive approach to topics of clinical, 
economic or political importance in southern African health systems. It is not an opportunity 
to put forward unsubstantiated opinions! 
  
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from Africa, 
preferably southern Africa unless the condition is common to all African countries, and must 
be either a completely new description of a clinical condition or result (use Google!) or a case 
that highlights important practice or management issues. 
  
Please use the following format for case reports: 
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• Title of case: do not include the words ‘a case report’ in the title 
• Summary/abstract:  up to 150 words summarising the case presentation and outcome 
• Background: why is this case important and why did you write it up? 
• Case presentation: presenting features, medical, social, family history as appropriate 
• Case management: should be according to best practice, and if not, please explain why 
• Investigations, if relevant: save space by simply saying ‘normal’ if, for example, renal function 
was completely normal, rather than listing normal results, highlight the abnormal – or indeed 
the normal if this is clinically significant 
• Differential diagnosis, if relevant 
• Treatment, if relevant 
• Outcome and follow-up 
• Discussion – a VERY BRIEF review of similar published cases 
• Teaching points: 3 - 5 bullet points 
• References: as per the SAMJ house style 
• Tables and figures: keep to a minimum. Use clinical images where relevant – we need hi-res 
versions for print, and identifiable persons must have a consent form 
• Patient consent: please include a statement about patient consent to a written case report. 
This should be uploaded as a supplementary file. 
  
Clinical trials 
Guideline word limit: 4000 words 
  
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should be 
registered with the appropriate national clinical trial registry (or any international primary 
register, if relevant), and the trial registration number should be cited at the end of the 
abstract. Since 1st December 2005, all clinical trials conducted in South Africa have been 
required to be registered in the South African National Clinical Trials Register. The SAMJ therefore 
requires that clinical trials be registered in the relevant public trials registry at or before the 
time of first patient enrollment as a condition for publication. The trial registry name and 
registration number must be included in the manuscript. 
  
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
  
Review articles 
Guideline word limit: 4 000 words 
  
These are welcome, but should be either commissioned or discussed with the Editor before 
submission. A review article should provide a clear, up-to-date account of the topic and be 
aimed at non-specialist hospital doctors and general practitioners. 
  
Please ensure that your article includes: 
• Abstract: unstructured, of about 100-150 words, explaining the review and why it is important 
• Methods: Outline the sources and selection methods, including search strategy and keywords 
used for identifying references from online bibliographic databases. Discuss the quality of 
evidence. 
• When writing: clarify the evidence you used for key statements and the strength of the 
evidence. Do not present statements or opinions without such evidence, or if you have to, say 
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that there is little or no evidence and that this is opinion. Avoid specialist jargon and 
abbreviations, and provide advice specific to southern Africa. 
• Personal details: Please supply your qualifications, position and affiliations and MP number 
(used for CPD points); address, telephone number and fax number, and your e-mail address; 
and a short personal profile (50 words) and a few words about your current fields of interest. 
  
Correspondence (Letters to the Editor) 
Guideline word limit: 500 words 
  
Letters to the editor should relate either to a paper or article published by the SAMJ or to a 
topical issue of particular relevance to the journal’s readership 
  
• May include only one illustration or table 
• Must include a correspondence address. 
  
Book reviews 
Guideline word limit: 400 words 
Should be about 400 words and must be accompanied by the publication details of the book. 
Provide a hi-res image of the cover if possible (with permission from the copyright holder). 
  
Obituaries 
Guideline word limit: 400 words 
Should be offered within the first year of the practitioner’s death, and may be accompanied 
by a photograph. 
  
Guidelines  
Guidelines should always be discussed with the Editor prior to submission. 
  
Because of the intensive review process required to ensure Guidelines are independent, 
evidence-based and free from commercial bias, they are usually published as a supplement 
to the SAMJ, the costs of which must be covered by sponsorship, advertising or payment by 
the guideline authors/association. We will provide a quote based on the expected length of 
the guideline and whether it is to appear online only, or in print, which must be accepted by 
the body putting the guidelines together before submitting the work to the SAMJ. 
  
The Editor reserves the right to determine the scheduling of supplements. Understandably, a 
delay in publication must be anticipated dependent upon editorial workflow. 
All guidelines should include a clear, transparent statement about all sources of funding and 
an explicit, clear statement of conflicts of interest of any of the participants in the guidelines 
about industry funding for lectures, research, conference participation etc.  
All guidelines should be structured according to Agree II. 
Please access this website before putting the guidelines together, download the Agree 11 
instrument and use this to put the guidelines together. 
All submitted guidelines will be sent to the local Agree II appraisal committee for review and 
must be endorsed by an appropriate body prior to consideration and all conflicts of interest 
expressed. 
  
A structured abstract not exceeding 400 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered 
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consecutively (e.g. 1. Introduction; 1.1 Definitions; 2.etc.) and summarised in a Table of 
Contents. 
  
Illustrations/photos/scans 
• If illustrations submitted have been published elsewhere, the author(s) should provide consent 
to republication obtained from the copyright holder. 
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
• All images must be of high enough resolution/quality for print. 
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
• Ensure all graph axes are labelled appropriately, with a heading/description and units (as 
necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 
etc. 
• Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to show 
the tumour. 
• Each image must be attached individually as a 'supplementary file' upon submission (not solely 
embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc. 
  
Tables 
• Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
• Large tables will generally not be accepted for publication in their entirety. Please consider 
shortening and using the text to highlight specific important sections, or offer a large table as 
an addendum to the publication, but available in full on request from the author 
• Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in the 
text. 
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
• Ensure each table has a concise title and column headings, and include units where necessary. 
• Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then 
** †† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
  
Rather: 
Each row of data must have its own proper row: 
  
Do not: use separate columns for n and %: 
  
Rather: 
Combine into one column, n (%): 
  
Do not: have overlapping categories, e.g.: 
  
Rather: 
Use <> symbols or numbers that don’t overlap: 
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References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
• Authors must verify references from original sources. 
• Citations should be inserted in the text as superscript numbers between square brackets, e.g. 
These regulations are endorsed by the World Health Organization,[2] and others.[3,4-6] 
• All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). 
• Approved abbreviations of journal titles must be used; see the List of Journals in Index Medicus. 
• Names and initials of all authors should be given; if there are more than six authors, the first 
three names should be given followed by et al. 
• Volume and issue numbers should be given. 
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
• Wherever possible, references must be accompanied by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
  
Some examples: 
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about 
glaucoma. Stat Med 1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182 
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 
1975:96-101. 
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading 
Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms of 
Disease. Philadelphia: WB Saunders, 1974:457-472. 
• Internet references: World Health Organization. The World Health Report 2002 - Reducing 
Risks, Promoting Healthy Life. Geneva: WHO, 2002. http://www.who.int/whr/2002 (accessed 
16 January 2010). 
• Legal references 
•              Government Gazettes: 
National Department of Health, South Africa. National Policy for Health Act, 1990 (Act No. 116 
of 1990). Free primary health care services. Government Gazette No. 17507:1514. 1996. 
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the notice 
number in this Gazette. 
•              Provincial Gazettes: 
Gauteng Province, South Africa; Department of Agriculture, Conservation, Environment and 
Land Affairs. Publication of the Gauteng health care waste management draft regulations. 
Gauteng Provincial Gazette No. 373:3003, 2003. 
•              Acts: 
South Africa. National Health Act No. 61 of 2003. 
•              Regulations to an Act: 
South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic medicine 
services. Government Gazette No. 35099, 2012. (Published under Government Notice R176). 
•              Bills: 
 55 
 
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006. 
•              Green/white papers: 
South Africa. Department of Health Green Paper: National Health Insurance in South Africa. 
2011. 
•              Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another:  Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate Cape, (G) 
Gauteng, and so on. 
NOTE: no . after the v 
• Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher 
place: Publisher name, year; pages. 
• Cited manuscripts that have been accepted but not yet published can be included as references 
followed by '(in press)'. 
• Unpublished observations and personal communications in the text must not appear in the 
reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
  
From submission to acceptance 
Submission and peer-review 
To submit an article: 
• Please ensure that you have prepared your manuscript in line with the SAMJ requirements. 
• All submissions should be submitted via Editorial Manager 
• The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Author Agreement form 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions for published 
images, etc. 
• Once the submission has been successfully processed on Editorial Manager, it will undergo a 
technical check by the Editorial Office before it will be assigned to an editor who will handle the 
review process. If the author guidelines have not been appropriately followed, the manuscript 
may be sent back to the author for correcting. 
  
Peer-review process 
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Production process 
The following process will follow: 
1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor (CE). 
2. The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for typesetting. 
3. If the CE has an author queries, he/she will contact the corresponding author and send 
them the copyedited Word doc, asking them to solve the queries by means of track 
changes or comment boxes. 
4. The authors are typically asked to respond within 1-3 days. Any comments/changes 
must be clearly indicated e.g. by means of track changes. Do not work in the original 
manuscript - work in the copyedited file sent to you and make your changes clear. 
5. The CE will finalise the article and then it will be typeset. 
6. Once typeset, the CE will send a PDF of the file to the authors to complete their final 
check, while simultaneously sending to the 2nd-eye proofreader. 
 57 
 
7. The authors are typically asked to complete their final check and sign-off within 1-2 
days. No major additional changes can be accommodated at this point. 
8. The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
  
Changing contact details or authorship 
Please notify the Editorial Department of any contact detail changes, including email, to 
facilitate communication. 
  
  
Publication 
Online v. print 
The SAMJ is an online journal. The online version of the journal is the one that has the widest 
circulation, is indexed by bibliographic databases including PubMed and SciELO, and is 
accessible in academic libraries. A printed edition , containing material selected by the Editor 
is also published each month and distributed to the membership of the South African Medical 
Association. 
  
  
Online 
• The full text of all accepted articles is published in full online, open access. 
• Citation information of each article is based on its online publication. 
• You may want to make use of the advantages of online publication e.g. specify web links to 
other sources, images, data or even a short video. 
  
Print 
• Not all articles will be selected for print. 
• An article may be selected for print in a different month from that in which it was published 
online. 
• Research articles will appear in abstract form only, if selected for a print edition. 
  
Errata and retractions 
Errata 
Should you become aware of an error or inaccuracy in yours or someone else’s contribution 
after it has been published, please inform us as soon as possible via an email to 
publishing@hmpg.co.za,including the following details: 
• Journal, volume and issue in which published 
• Article title and authors 
• Description of error and details of where it appears in the published article 
• Full detail of proposed correction and rationale 
  
We will investigate the issue and provide feedback. If appropriate, we will correct the web 
version immediately, and will publish anerratum  in the next issue. The correction will be 
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indexed, as PubMed has a function for linking errata back to the original article. All 
investigations will be conducted in accordance with guidelines provided by the Committee on 
Publication Ethics (COPE). 
  
Retractions 
Retraction of an article is the prerogative of either the original authors or the editorial team 
of HMPG. Should you wish to withdraw your article before publication, we need a signed 
statement from all the authors. 
  
Should you wish to retract your published article, all authors have to agree in writing before 
publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
• Journal, volume and issue to which article was submitted/in which article was published 
• Article title and authors 
• Description of reason for withdrawal/retraction. 
  
We will make a decision on a case-by-case basis upon review by the editorial committee in 
line with international best practices. Comprehensive feedback will be communicated with the 
authors with regard to the process. In case where there is any suspected fraud or professional 
misconduct, we will follow due process as recommended by the Committee on Publication 
Ethics (COPE), and in liaison with any relevant institutions. 
  
When a retraction is published, it will be linked to the original article. 
  
Indexing 
The SAMJ has an impact factor of 1.5. 
Published articles are covered by the following major indexing services. As such articles 
published in the SAMJ are immediately available to all users of these databases, guaranteed 
a global and African audience: 
• Index Medicus (Medline/PubMed)  
• ExcerptaMedica (EMBASE) 
• Biological Abstracts (BIOSIS) 
• Science Citation Index (SciSearch) 
• Current Contents/Clinical Medicine 
• Scopus 
• AIM 
• AJOL 
• Crossref 
• Sabinet 
• Scielo 
  
Sponsored supplements 
Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
  
  
Submission Preparation Checklist 
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As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that 
do not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. All research already published as ‘Conference proceedings’ needs to be 
substantially re-written, with a new title, a new abstract and new and important results 
to back up any study before it will be considered for a new publication. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word document format. The text is single-spaced, in 12-
point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (PDF or jpeg). These must be submitted individually as 'supplementary files' 
(not solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
  
Copyright Notice 
Copyright of published material remains in the Authors’ name. This allows authors to use their 
work for their own non-commercial purposes without seeking permission from the Publisher, 
subject to properly acknowledging the Journal as the original place of publication. 
 Authors are free to copy, print and distribute their articles, in full or in part, for teaching 
activities, and to deposit or include their work in their own personal or institutional database 
or on-line website. Authors are requested to inform the Journal/Publishers of their 
desire/intention to include their work in a thesis or dissertation or to republish their work in 
any derivative form (but not for commercial use).  
 Material submitted for publication in the SAMJ is accepted provided it has not been published 
or submitted for publication elsewhere. Please inform the editorial team if the main findings 
of your paper have been presented at a conference and published in abstract form, to avoid 
copyright infringement. 
  
Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. The 
names, personal particulars and email addresses entered in this website will be used only for 
the stated purposes of this journal and will not be made available to third parties without the 
user’s permission or due process. Users consent to receive communication from the SAMJ for 
the stated purposes of the journal. Queries with regard to privacy may be directed 
to publishing@hmpg.co.za. 
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2.7 Letter to the editor of the  South African Medical Journal
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2.8 South African Medical Journal’s comments 
From: SAMJ <em@editorialmanager.com> 
Date: 2019/07/01 11:33 (GMT+02:00) 
To: Sashmi Moodley <sashmi.moodley@yahoo.com> 
Subject: Decision on your Submission to SAMJ 
  
Ref.: SAMJ14200 
A retrospective description of primary immunodeficiency diseases at Red Cross war Memorial 
Children's Hospital, Cape Town, South Africa, 1975 - 2017 
South African Medical Journal 
 
Dear Dr Moodley, 
 
Reviewers have now commented on your paper. You will see that they are advising that you revise 
your manuscript.  
 
For your guidance, reviewers' comments are appended below. 
 
If you are prepared to undertake the work required, please submit a list of changes or a rebuttal 
against each point which is being raised when you submit the revised manuscript. 
 
Your revision is due by Jul 29, 2019. Please let us know if you require additional time.  
 
To submit a revision, go to https://www.editorialmanager.com/samj/ and log in as an Author. You will 
see a menu item called Submission Needing Revision.  
 
Best wishes 
 
Bridget Farham, PhD 
Editor 
South African Medical Journal 
 
Reviewers' comments: 
 
Reviewer's Responses to Questions 
 
Please comment on your General impression of this manuscript - bear the following in mind:  
 
Is the article relevant? 
 
Does it offer anything new? 
 
Are there similar studies in our region/outside the region? 
 
Does it add to the existing medical body of knowledge? 
 
On first glance, are the methods, results and conclusions reasonable? 
 
Do the conclusions actually draw on the results? 
 
Does the article have a clear message? 
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Will it help SAMJ readers make better clinical decisions and, if so, how? 
 
Is a general medical journal the right place for it? 
 
 
Reviewer #1: This is an interesting and important study as it documents a neglected field of 
paediatrics, updating previous literature by attempting to comprehensively include children managed 
at a children's hospital across all sub-specialist disciplines. 
The study also serves to raise awareness among general paediatricians about the importance of 
considering PID in children presenting with recurrent infections/ and or particular medical conditions. 
the importance being that there may be specific, life-saving and curative treatment available as well 
as preventative measures that could limit disease complications 
  
 
 
Please comment on the Methods and analysis presented in this manuscript  
 
Study design  
 
Is the research question and planned outcomes clearly defined? 
 
Was the sample adequate and sufficiently described? 
 
Are the methods adequately described and appropriate to the study objectives? 
 
Statistical considerations 
 
Are simple statistical methods applied appropriately? 
 
 
 
Reviewer #1: The study design and methods are clearly and succinctly laid out. Descriptive statistics 
are used to adequately describe the data 
  
  
 
 
Please comment on the Results, Discussion and Conclusions presented in this manuscript  
 
Results 
 
Is the population/sample adequately described? 
 
Are the results clearly presented? 
 
Are they credible and do they answer the research question? 
 
Are tables clear and useful, not simply mirroring data discussed in the Results text? 
 
 
Reviewer #1: The results are clearly presented and provide good information that complements the 
text in the results section. 
The population and patient selection are well described 
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Some revised formatting of the two figures would enhance the clarity(reduce blurring) of the inserted 
images. 
  
  
  
  
 
 
Discussion  
 
Are the results well discussed in light of previous evidence and the literature? 
 
Are the limitations of the study sufficiently discussed?/ Are the strengths and weakness discussed? 
 
Is the meaning and relevance of the study discussed? 
 
 
Reviewer #1: The results are well discussed and appropriately compared with relevant international, 
particularly, sub-Saharan African data. The database has been meticulously built however, some 
acknowledgement of the fact that there are likely more cases that are completely missed by 
management in areas where the possibility of PID is not considered, additionally, some of the PIDs 
may be present in milder forms. 
  
  
  
  
 
 
Conclusion  
 
Are the implications of the research summarised? 
 
Do the authors make relevant recommendations for future research or application? 
 
Reviewer #1: The researchers are to be acknowledged for achieving their stated aims and for seeking 
to raise awareness of this important set of paediatric conditions and in their efforts in attempting to be 
as comprehensive as possible within the limitations described. 
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Reviewer #1: Some minor typos need correction, insertion of missing legends to tables and figures 
and improvement on the resolution quality of the two figures is suggested 
 
There is additional documentation related to this decision letter. To access the file(s), please click the 
link below. You may also login to the system and click the 'View Attachments' link in the Action 
column. 
View Attachments 
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2.9 Author response to South African Medical Journal 
 
 UNIVERSITY OF CAPE TOWN 
DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH 
RED CROSS WAR MEMORIAL CHILDREN’S HOSPITAL 
KLIPFONTEIN ROAD 
RONDEBOSCH 
                               7701 
TEL:  +27 21 658 5111 
FAX:  +27 21 689 1287 
3 July 2019 
The Editor 
South African Medical Journal 
 
Dear Dr Farham  
Ref.: SAMJ14200 
A retrospective description of primary immunodeficiency diseases at Red Cross War 
Memorial Children's Hospital, Cape Town, South Africa, 1975 - 2017 
 
Thank you for your much awaited reply. I hereby submit my list of changes to the manuscript 
as guided by the reviewer. 
Hope this meets with the team’s approval.  
 
Yours in good faith  
Dr Sashmi Moodley  
MBCHB (UKZN), DCH (SA), Dip HIV Man(SA), FCPaed (SA) 
 
Response to reviewer’s comments : 
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1. Please comment on your General impression of this manuscript - bear the following in 
mind:  
 
Is the article relevant? 
 
Does it offer anything new? 
 
Are there similar studies in our region/outside the region? 
 
Does it add to the existing medical body of knowledge? 
 
On first glance, are the methods, results and conclusions reasonable? 
 
Do the conclusions actually draw on the results? 
 
Does the article have a clear message? 
 
Will it help SAMJ readers make better clinical decisions and, if so, how? 
 
Is a general medical journal the right place for it? 
 
 
Reviewer #1: This is an interesting and important study as it documents a neglected field of 
paediatrics, updating previous literature by attempting to comprehensively include children managed 
at a children's hospital across all sub-specialist disciplines. 
The study also serves to raise awareness among general paediatricians about the importance of 
considering PID in children presenting with recurrent infections/ and or particular medical conditions. 
the importance being that there may be specific, life-saving and curative treatment available as well 
as preventative measures that could limit disease complications 
  
Author: Appreciated. 
 
 
2. Please comment on the Methods and analysis presented in this manuscript  
 
Study design  
 
Is the research question and planned outcomes clearly defined? 
 
Was the sample adequate and sufficiently described? 
 
Are the methods adequately described and appropriate to the study objectives? 
 
Statistical considerations 
 
Are simple statistical methods applied appropriately? 
 
 
 
Reviewer #1: The study design and methods are clearly and succinctly laid out. Descriptive statistics 
are used to adequately describe the data 
Author: Appreciated. 
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Reviewer comment X2: Could this not be rectified, particularly if this is a unique database not only 
for the study hospital but for RSA? 
 
Author response: We did rectify this problem in the current study. To make this clear, the final sentence 
of the section entitled “Study design and setting” was changed to: To address this gap in the PID 
database and describe the full spectrum of PIDs managed or supported by all sub-specialist services 
at RCWMCH between 1 January 1975 and 31 December 2017, the infectious diseases service 
collaborated with several specialist / sub-specialist services managing children with PIDs.  
 
 
3. Please comment on the Results, Discussion and Conclusions presented in this manuscript  
 
Results 
 
Is the population/sample adequately described? 
 
Are the results clearly presented? 
 
Are they credible and do they answer the research question? 
 
Are tables clear and useful, not simply mirroring data discussed in the Results text? 
 
 
Reviewer #1: The results are clearly presented and provide good information that complements the 
text in the results section. 
The population and patient selection are well described 
 
Some revised formatting of the two figures would enhance the clarity(reduce blurring) of the inserted 
images. 
Author: Apologies for the blurring of the figures in the manuscript. They have been revised in a PDF 
version and will be uploaded as separate files from the manuscript. 
 
 
4. Discussion  
 
Are the results well discussed in light of previous evidence and the literature? 
 
Are the limitations of the study sufficiently discussed? Are the strengths and weakness discussed? 
 
Is the meaning and relevance of the study discussed? 
 
 
Reviewer #1: The results are well discussed and appropriately compared with relevant international, 
particularly, sub-Saharan African data. The database has been meticulously built however, some 
acknowledgement of the fact that there are likely more cases that are completely missed by 
management in areas where the possibility of PID is not considered, additionally, some of the PIDs 
may be present in milder forms. 
Author: Thank you for this comment. We agree that PIDs were probably missed during the study 
period. Consequently, the following sentence was added to the section entitled “strengths and 
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limitations”: “Furthermore, it is likely that more cases of PID were missed during the study period 
because either PIDs was not considered or the children presented with milder PID phenotypes.”  
 
 
5. Conclusion  
 
Are the implications of the research summarised? 
 
Do the authors make relevant recommendations for future research or application? 
 
Reviewer #1: The researchers are to be acknowledged for achieving their stated aims and for seeking 
to raise awareness of this important set of paediatric conditions and in their efforts in attempting to be 
as comprehensive as possible within the limitations described. 
Author: Appreciated. 
  
 Reviewer comment X5: Not part of your conclusion. Belongs in the discussion.  
 Author: The first 3 sentences of the conclusion have been moved to the first paragraph of the 
discussion. Consequently, minor changes were made to the first paragraph of the discussion to 
accommodate this revision.   
 
 
6. Reviewer #1: Some minor typos need correction, insertion of missing legends to tables and figures 
and improvement on the resolution quality of the two figures is suggested 
Author: Apologies for typos. They have been corrected as directed. Legends have been inserted to 
tables and figures. The 2 figures have been clarified and resaved in PDF format as separate files from 
the manuscript.  
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2.10 South  African Medical Journal ‘s letter of acceptance for 
publication  
 
SAMJ <em@editorialmanager.com> 
To:Sashmi Moodley 
Jul 10 at 7:58 AM 
CC: "Brian Eley" brian.eley@uct.ac.za, "Elizabeth Goddard" liz.goddard@uct.ac.za, "Michael Levin" 
michael.levin@uct.ac.za, "Chris Scott" chris.scott@uct.ac.za, "Ann Van Eyssen" 
annvaneyssen@icloud.com, "Alan Davidson" alan.davidson@uct.ac.za, "Rik De Decker" 
rik.dedecker@uct.ac.za, "Jo Wilmshurst" jo.wilmshurst@uct.ac.za, "Ariane Spitaels" 
ariane.spitaels@uct.ac.za 
Ref.: SAMJ14200 
A retrospective description of primary immunodeficiency diseases at Red Cross War Memorial 
Children's Hospital, Cape Town, South Africa, 1975 - 2017 
South African Medical Journal 
 
Dear Dr Moodley, 
 
We are pleased to tell you that your work has now been accepted for publication in South African 
Medical Journal. 
  
Please note that as per the author guidelines, page-fee charges have been implemented since March 
2017 for all research articles. Please find payment form attached herewith. As soon as proof of 
payment and the completed form have been received, we will send your article into production. 
(Please note that we are unable to process American Express card payments). Please send proof of 
payment to claudian@hmpg.co.za 
 
 
Thank you for submitting your work to the journal. 
 
Best wishes 
 
Bridget Farham, PhD 
Editor 
South African Medical Journal 
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2.11 University of Cape Town  MMed guidelines  
 
 
(Excluding Public Health Medicine, Occupational Medicine and Family Medicine) 
As approved in PC: September 2017 
UNIVERSITY OF CAPE TOWN 
FACULTY OF HEALTH SCIENCES 
MMed Part III (minor dissertation) 
Guidelines for candidates, supervisors and examiners 
The MMed minor dissertation is one of three examination components of the MMed degree. This 
minor dissertation carries one third of the weight of a full master’s dissertation in terms of it’s credit 
weighting, i.e. 60 credits (nominally 600 hours of work). In order to register as a specialist in South 
Africa, the Health Professions Council of South Africa (HPCSA) requires all specialist trainees who 
register for training after 1 January 2011 to have completed a relevant research study. The MMed 
Part III fulfils HPCSA research requirements as well as research requirements by the specialties who 
include a research project as part of their examination process by the Colleges of Medicine of South 
Africa (CMSA). 
Educational aims 
The research project should demonstrate that the student: 
• can work independently and ethically under supervision (contributions/assistance must be 
acknowledged); 
• is sufficiently acquainted with the relevant literature to provide appropriate motivation for the 
research question; 
• can plan research or clinical audit (write a protocol), which is approved by an assessor group 
(delegated by the head of department) and ethics committee where relevant, that contributes new 
or additional data to the collective knowledge base (the specific data has not been presented as 
part of other research), but need not produce a unique contribution to the scientific literature; 
• uses an appropriate method/design/technique and analysis; 
• can adequately present and discuss the significance of the results of the study; 
• can present the study in an academically acceptable manner. 
Type and scope of the research 
The following types of studies are acceptable: 
• A clinical audit with or without a repeat data collection cycle; 
• A systematic review of the literature on its own with extraction and extrapolation of data OR a 
meta-analysis using recognised research methods (eg Cochrane, PRISMA); 
• A research study – pro-/retrospective lab or clinical or database review; 
• Description and analysis of a case series or cohort, deemed sufficient to supply new 
knowledge/data, even if only contextual or exploratory; 
• Epidemiological research; 
• Health service/systems/education research; 
• Qualitative research; 
Noting: 
• The sample size can be limited by time (Registrars have limited time allocated/available to 
collect data and write it up concurrently with their clinical training) - data collection and write 
up should be possible to complete within two consecutive or cumulative months. 
• Data analysis may use simple descriptive statistics alone – more advanced analysis can be 
used, but the student must demonstrate (in the write up) insight into the choice of analysis. 
MMed Minor dissertation guidelines (Excluding Public Health Medicine, Occupational Medicine and Family Medicine) 
As approved in PC: September 2017 
• The above limitations may be associated with the use of descriptive cohort studies based on 
medical record review; exploratory or pilot studies with small convenience samples; or audits 
without a repeat data collection cycle to prove quality improvement (QI). Despite limitations, 
these studies can provide an adequate basis for learning research methodology and can add 
new data to the collective knowledge base – they may also provide the basis for further 
publishable work such as a second audit to complete a full QI cycle. As long as these 
limitations are appropriately acknowledged, these studies should still be acceptable. 
• The topic, study design and scope of research may depend on the particular discipline and 
must be agreed on in consultation with the supervisor(s). The topic must be approved as 
being suitable for MMed dissertation by the Departmental Research Committee (DRC) and/or 
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a group appointed for this purpose by the head of department. 
Submission formats 
The dissertation may be presented in one of three formats: 
I: Publication-ready format; 
II: Published (or accepted for publication) Paper format 
III: Monograph format. 
As disciplines differ in their requirements, it is important that the format chosen is acceptable to the 
discipline and appropriate College within the CMSA. 
Research protocol 
NOTE: All communication from UCT regarding the MMed and the examination process will 
occur via student UCT e-mailaddress – [student number]@myuct.ac.za. Students must also 
make sure they have username and password and are able to access the PeopleSoft Student 
Administration Self Service. 
Candidates intending to register for the MMed Part III are required to submit a research protocol for 
approval to their respective Departmental Research Committees (DRC). The research protocol should 
briefly summarise the existing knowledge on the topic and justify the research question; it should 
clearly describe the objectives and methodology and should be structured according to the guidelines 
in Form FHS015. Write a synopsis according to Form FHS014. Complete a new protocol 
application form FHS 013. All FHS forms are available at 
http://www.health.uct.ac.za/fhs/research/humanethics/forms. 
The candidate must then obtain approval from the UCT Faculty of Health Sciences Research Ethics 
Committee (HREC) prior to conducting their research. Studies that involve the audit of clinical records 
or services also require formal HREC approval. Any primary research that is taking place in a 
provincial or local authority health facility, such as public sector hospitals or clinics, must also be 
submitted to the provincial government for approval, after the UCT Research Ethics Committee 
approval has been obtained. Approval to access public sector facilities for research is needed 
for all provincial and local authority facilities. There are five points where approval for research 
can be applied for; Groote Schuur Hospital, Red Cross War Memorial Children’s Hospital, Tygerberg 
Hospital), the local authorities and "all other province". Teaching hospitals and the local authorities 
approve research projects in-house. "All other province" approvals are done via the Directorate: 
Health Impact Assessment (Sub-directorate: Research) at provincial head office. If research crosses 
these boundaries, up to five approvals may be needed. Further details can be found at 
https://www.westerncape.gov.za/general-publication/health-research-approval-process 
The Provincial Health Research Committee does not approve research proposals itself, but oversees 
this approval process by reviewing difficult applications on referral. 
The proposal contents should comply with requirements stipulated in Form D1a. This full research 
protocol together with FHS 013, a copy of the HREC approval letter and completed Forms D1 
(Protocol approval), D3 (supervisor appointment form), and D1a must be submitted to the 
postgraduate administration office, for approval by the Professional Masters Committee (PMC) Chair 
MMed Minor dissertation guidelines (Excluding Public Health Medicine, Occupational Medicine and Family Medicine) 
As approved in PC: September 2017 
and the Board of the Faculty of Health Sciences, prior to commencement of the research. If the title, 
aims, objectives or any other aspect of the research change following initial submission, an 
ammendment must be submitted to HREC. All D-forms are available from the post graduate 
faculty office or on the UCT Vula Mmed/Mphil site (All registrars and supervisors must be 
added to this site – your departmental programme manager must send names and email 
addresses to gregory.doyle@uct.ac.za in order to be added to the site). 
Timelines 
Submission of the research protocol for approval should generally be made within the first 12 - 24 
months of the registrar programme (this varies between disciplines). Heads of Departments or 
Divisions should meet with their registrars at least biannually to review progress towards their 
research project. Unless otherwise stipulated by your Division / Department, the research project 
should generally be completed by the end of Year 3. For a number of specialties, a dissertation must 
be submitted before writing the Part II examination. Often the research component of specialist 
training is only initiated after successful completion of the Part I examination. 
Supervisors 
The supervisor must: have research experience, ideally a Master’s degree, equivalent (eg appropriate 
publications), or higher; be able relate to the candidate’s research project; be available for regular 
discussion and advice; and be someone with whom the candidate can develop a good working 
relationship. If the primary supervisor does not have adequate experience, then a secondary 
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supervisor who has appropriate experience will need to be appointed in addition. Supervisors who 
have not had extensive experience supervising are required to attend a supervisor training 
course. Where specialised equipment and/or laboratory work is required for the study, the supervisor 
should assist in facilitating access to appropriate facilities. 
The primary supervisor may be based outside the candidate’s home department, faculty or university. 
In such a case, a member of UCT staff will also be required as co-supervisor in addition to the primary 
supervisor, to serve as a guide and link to UCT faculty and discipline-specific procedures. Primary 
supervisors retain responsibilities to the candidate and the university until the dissertation process is 
complete. In addition to the forms mentioned above, the supervisor and student must complete D2a 
which describes the contractual memorandum of agreement (MOU) between supervisor and student 
regarding the minor dissertation. 
The dissertation 
Submission of all formats of the dissertation should include the following: 
The title page should contain the candidate’s name, dissertation title and the name of the university. 
It must also state the degree, e.g. Master of Medicine (MMed) in, Medicine, Paediatrics, etc. 
The Table of contents 
The declaration page should include a statement to the effect that the research reported is based on 
independent work performed by the candidate and that neither the whole work nor any part of it has 
been, is being, or is to be submitted for another degree to any other university. It must also state that 
this work has not been reported or published prior to registration for the abovementioned degree. 
The abstract should summarise the study rationale, methods, results, discussion and conclusion in 
fewer than 500 words. 
Acknowledgements and contributions. This section should acknowledge and describe the support 
or input from supervisors and other co-author(s) if applicable. In a dissertation derived from work 
started by others, e.g. analysis of data collected for another project, the origin of the data and the 
candidate’s contribution must be clearly stated. The candidate must complete the dissertation after 
his/her registration for the degree and therefore under supervision. In a published manuscript from a 
MMed Minor dissertation guidelines (Excluding Public Health Medicine, Occupational Medicine and Family Medicine) 
As approved in PC: September 2017 
multi-authored project, the candidate must be first author. 
List of Tables 
List of Figures 
Abbreviations 
The remainder of the dissertation must be presented in one of three formats: 
I: Publication-ready format; 
II: Published (or accepted for publication) paper format 
II: Monograph format. 
I: Publication format 
The dissertation must include a manuscript in publication-ready format. The body of the dissertation 
must be structured as follows: 
Chapter 1: Introduction and Literature review 
This section must give the background and context of the research question and must include a 
review of the literature relevant to the subject matter and methods of the study. The review should 
summarise and interpret the existing knowledge in the field with relevance to the research setting and 
should identify knowledge gaps and hence the rationale for the dissertation. This chapter should end 
with a clear statement reflecting the aims and objectives of the research reported in the publicationready 
manuscript. References quoted in this chapter should appear at the end of the chapter, not at 
the end of the thesis. This chapter should be between 2 000 and 5 000 words. 
Chapter 2: Publication-ready Manuscript 
This chapter must be presented in the form of a manuscript of an article for a named peer reviewed 
journal, meeting all the requirements of the “Instructions for Authors” of that journal, including the 
word count and referencing style. Unless specially motivated, the journal chosen should allow for at 
least 2000 words (not more than 5000 words) excluding abstract, tables, figures and references. The 
“Instructions to Authors” of the journal must be appended. The co-authors should be listed in the 
appropriate order, and each of their contributions to the manuscript stated. The journal chosen for 
publication must be appropriate to the subject matter of the dissertation and listed in the citation index 
of the Institute for Scientific Information (ISI) or accredited by the Department of Education 
http://www.lib.uct.ac.za/medical/index.php?html=/libs/accredjnls.htm&libid=24); other journals with 
similar review processes, particularly South African journals may be acceptable if permission is 
obtained from the PMC Chair after appropriate motivation is provided. 
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Note 1: In this format, the candidate need not have submitted the article for publication, nor is the 
acceptance of the article for publication a requirement for passing the degree. However, the norm is to 
publish the study with the supervisor(s) as co-author(s), and candidates are strongly encouraged to 
submit their manuscript for publication after examination of the minor dissertation. 
NOTE 2: IF THE RESEARCH IS A FULL SYSTEMATIC REVIEW, THERE IS NO NEED FOR A 
SEPARATE CHAPTER 1 – THE REVIEW SHULD BE SUBMITTED AS ONE CHAPTER. 
Appendices 
Append all supporting documents including: 
• Questionnaire/data capture instrument(s) 
• Consent forms and any related participant information sheets 
• Technical appendices, including, if considered necessary, any additional tables not included 
in the main manuscript for the examiner to have available. These should be accompanied by 
a brief narrative. 
• Official Ethics approval letter from the Faculty Research Ethics Committee (except for a full 
systematic review) and any other approvals required (e.g. Provincial Government). 
• Instructions to Authors of the chosen journal 
MMed Minor dissertation guidelines (Excluding Public Health Medicine, Occupational Medicine and Family Medicine) 
As approved in PC: September 2017 
II: Published (or accepted for publication) paper format 
A manuscript that has already been published or accepted for publication in a journal that is listed in 
the citation index of the Institute for Scientific Information (ISI) or accredited by the Department of 
Education (other journals with similar review processes, particularly South African journals may be 
acceptable if permission is obtained from the PMC Chair after appropriate motivation is provided), 
may be submitted if the candidate was the first author, the candidate’s contribution was 
completed under supervision during his/her registration for the degree, and the paper is in line 
with the educational aims and scope of research described in the first part of this document. 
The dissertation must be submitted in similar format to the publication-ready format – the only 
differences being: a separate literature review is not required; the accepted publication is submitted 
as a single chapter following the same format as described above under “Chapter 2”; and the 
reviewer comments from the journal should be attached as an appendix. When this format is used, 
the contributions of all the authors must be very clearly stated under a sub-heading in the 
“Acknowledgments and contributions” section in the first part of the thesis. 
III: Standard monograph format 
Some disciplines and constituent Colleges of the Colleges of Medicine of South Africa require a 
standard monograph presented in a comprehensive and scholarly style to be submitted as part of the 
examination. The length is typically 16 000 to 20 000 words in length, but may vary. If the length is not 
stipulated, the monograph should be 6000 – 16000 words, excluding references and tables. 
A recommended structure for the body of the dissertation is as follows; 
Chapter 1: Introduction and Literature review 
(see guidelines above) 
Chapter 2: Methods 
Material and methods of the study must be fully described and factually presented. 
Chapter 3: Results 
Chapter 4: Discussion and conclusions 
Appendices 
(see guidelines above - omit the instructions to authors) 
Language and writing 
Clear, grammatically correct English is essential. 
Supervisors may assist candidates in developing scientific communication skills but they are not 
required to do detailed editing or correction of spelling, grammar, or style. Training in scientific writing 
is available at the Health sciences Writing Centre. Registrars need to make an appointment via the 
website: http://www.writingcentre.uct.ac.za/about/healthsciences 
Candidates should refer to Form D4, Guidelines on the Layout and Style of the Dissertation or Thesis. 
As long as the dissertation is readable and internally consistent, any of a number of styles are 
acceptable. For a publication-ready manuscript, references should be formatted according to the 
instructions to authors for the journal selected, and candidates should use the same style throughout 
their dissertation. For a monograph format manuscript, the Harvard style for referencing is 
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downloaded from the ICTS or UCT library website. 
Candidates should look at previous examples of Master’s dissertations in the library. Master’s 
dissertations are available in the Health Sciences Library. A search will need to be done to obtain a 
list of titles and authors. This search can be done using search words (e.g. dissertation, health, health 
sciences, etc.). The librarian can be asked for assistance. Some of these dissertations are available 
via: http://www.medical.lib.uct.ac.za/hsl/theses-dissertations 
Annual approval 
After 1 year, apply to HREC for continuing approval Form FHS016 (for intervention study) or FHS017 
(for record review) or submit a study closure form, FHS010, if the study is complete. If registration in 
MMED III is required for more than one year then complete form D2(b) and submit to Post Grad Office 
when re-registering. 
Submission of dissertations 
On completion, the dissertation and a Turn-it-in originality report must be submitted to the Faculty 
Postgraduate Office. The candidate should inform the Faculty Officer one month in advance of the 
intention to submit, using Form D8 (Intention to submit) online with PeopleSoft system and should 
subsequently submit their dissertation using the same system – guidelines for this process and the 
use of Turn-it-in are on the Mmed/Mphil Vula Website and detailed guidelines are also available 
in the UCT student help document: “ Digital submission of a thesis/dissertation for 
examination and library access”. This document is available online at 
http://www.uct.ac.za/usr/current_students/postgrad/digital_upload_dissertations_theses.pdf 
Supervisors will be requested by the Faculty Postgraduate Officer to submit a letter supporting 
submission, and clearly specifying whether the format of submission, so that the appropriate 
instructions are sent to the examiners. This letter should be supplied by the primary supervisor. If this 
supervisor is external, the internal supervisor must be kept informed at every stage of the process. 
Please note: In the event that any of your external examiners request a hard copy of your 
dissertation/ thesis, you will be required to supply this. The Faculty office will inform you should this be 
necessary. 
Specific submission requirements may be set by individual disciplines or constituent Colleges of the 
CMSA, and registrars are obliged to ensure that their research projects and dissertations meet these 
specific requirements. UCT Dissertation submission deadlines: 
1. March 15th for June graduation 
2. August 15th for December graduation 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the beginning of the 
first quarter (first day of academic year), and before the start of the second semester (mid July) to 
qualify for a 50% fee rebate. 
Examiners 
The full dissertation will be submitted for examination through the Postgraduate Office to two 
examiners (nominated by the supervisors and HOD) – at least one examiner must be external to 
UCT. An internal examiner must not be involved in the research. 
It is the supervisors’ responsibility to submit names of three potential examiners (or two examiners 
who have already agreed to examine pending approval of the Post Graduate Office) to the Faculty 
Officer when the candidate is ready to submit. Appointment of examiners from outside South Africa is 
encouraged. These nominations need to be approved by the Deputy Dean: Postgraduate Affairs on 
behalf of the Faculty Board and submitted to the Faculty Board for ratification via a Dean’s Circular. 
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Details required for each examiner are: academic qualifications, postal and/or physical address, 
telephone and fax numbers and e-mail address, and one paragraph description of their standing in 
the relevant field (drawn from their CV if need be). The examiners will be sent a copy of these 
guidelines as well as a guideline for marking. The candidate may not be informed of the identity of the 
examiners. After the outcome of the minor dissertation has been finalised, the examiners’ identities 
are made known if the examiners have indicated that they do not object to this. 
Publication agreement 
The university has a moral responsibilty to publish all research undertaken when publication is stated 
as an anticipated output. A candidate who fails to submit a manuscript to a journal for publication 
within 1 year of submission of their thesis, must accept that their supervisor(s) are entitled to publish 
their data on their behalf, with the student as co-author - this should be stated in the memorandum of 
understanding. 
 
